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INTRODUCTION
Peroxisome proliferator-activated receptors (PPARs) are
members of the ligand-activated nuclear hormone receptor
superfamily (1). Three PPAR isoforms ( ,  and  ) differ in
their tissue distribution and ligand specificity (1). PPAR-
is present in heart, kidney, and liver and appears to primarily
regulate genes involved in lipid and lipoprotein metabolism
(1, 2), whereas PPAR- expression is ubiquitous (3, 4) and
its physiological role is unclear (5). PPAR- is expressed pre-
dominantly in adipose tissue, with lower levels in muscle and
liver (6, 7). Although the physiological role of PPAR- has
not been clearly determined, it appears to be an important
transcriptional regulator of genes involved in glucose and
lipid metabolism. It was originally characterized as a regula-
tor of adipocyte differentiation and lipid metabolism. PPAR-
was also shown to be expressed in other cell types, includ-
ing T lympocytes and chondrocytes (8-10).
PPAR- can heterodimerize with at least one other mem-
ber of the steroid receptor superfamily, retinoid acid recep-
tor (RXR) (11). Ligand-activation of the PPAR- :RXR het-
erodimer has been shown to modulate the transcription of
genes involved in lipid metabolism, inflammation, and cell
differentiation (12). Recent evidence also shows that the nat-
ural receptor ligand for PPAR- , 15d-PGJ2 (13), and syn-
thetic antidiabetic thiazolidinedione drugs (e.g. BRL49653,
rosiglitazone [Rtz] and ciglitizone), inhibit macrophage and
monocyte activation (14) and suppress tumor cell growth
(15). Specific ligands for the PPAR- and RXR have been
shown to act synergistically to induce terminal differentia-
tion of human liposarcoma cells (16) in vitro and to enhance
insulin sensitivity in diabetic animals (17).
To maintain cartilage homeostasis, articular chondrocytes
synthesize cartilage-specific extracellular matrix molecules,
including type II collagen and sulfated proteoglycans (18).
This homeostasis is lost in cartilage diseases such as rheuma-
toid arthritis (RA) and osteoarthritis (OA), eventually lead-
ing to cartilage destruction. Cartilage destruction involves a
loss of differentiated chondrocyte phenotypes (i.e. dediffer-
entiation), which is characterized by the cessation of type II
collagen expression and onset of fibroblastic type I and type
III collagen expression (19). Interleukin-1 (IL- ) and tumor
necrosis factor  (TNF  ) have been shown to inhibit the syn-
thesis of cartilage components and to promote their degra-
dation by activating metalloproteinases (20). Concurrently
to these effects, they induce the production by chondrocytes
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15-Deoxy-
12,14-ProstaglandinJ2 Regulates Dedifferentiation through
Peroxisome Proliferator-Activated Receptor- -Dependent Pathway but
Not COX-2 Expression in Articular Chondrocytes
Peroxisome proliferator-activated receptors- (PPAR- ) is critical for phenotype
determination at early differentiation stages of mesenchymal cells, whereas its phy-
siological role is unclear. Therefore, we investigated the role of 15-deoxy-
12,14-pro-
staglandinJ2 (15d-PGJ2), the natural receptor ligand for PPAR- , on dedifferentia-
tion and inflammatory responses, such as COX-2 expression and PGE2 production,
in articular chondrocytes. Our data indicate that the 15d-PGJ2 caused a loss of dif-
ferentiated chondrocyte phenotype as demonstrated by inhibition of type II collagen
and proteoglycan synthesis. 15d-PGJ2 also induced COX-2 expression and PGE2
production. The 15d-PGJ2-induced dedifferentiation effect seems to be dependent
on PPAR- activation, as the PPRE luciferase activity increased and PPAR- an-
tagonist, BADGE, abolished type II collagen expression. However, BADGE did not
block 15d-PGJ2-induced COX-2 expression. Collectively, our findings suggest
that PPAR- -dependent and -independent mechanisms of 15d-PGJ2-induced ded-
ifferentiation and inflammatory responses in articular chondrocytes, respectively.
Additionally, these data suggest that targeted modulation of the PPAR- pathway
may offer a novel approach for therapeutic inhibition of joint tissue degradation.
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of inflammatory mediators such as prostaglandins, nitric oxi-
de (NO), and other reactive oxygen species (21). To date most
of the drugs marketed as nonsteroidal anti-inflammatory drugs
or corticosteroids are unable to prevent cartilage damage (22).
Thus, intense investigations are carried out to precise the
transduction pathways that impair cartilage homeostasis in
order to find new strategies that would be helpful to prevent
cartilage destruction.
In this study, we investigated whether 15d-PGJ2, PPAR-
activator, may modulate the differentiation and inflamma-
tion in rabbit articular chondrocytes. We report here that
PPAR- activation induces dedifferentiation but not inflam-
mation in articular chondrocytes. These results suggest that
PPAR- agonists may provide a new therapeutic approach
for RA and OA.
MATERIALS AND METHODS
Monolayer culture of rabbit articular chondrocytes and
experimental culture condition 
Rabbit articular chondrocytes were released from cartilage
slices of 2-week-old New Zealand white rabbits by enzyma-
tic digestion. Briefly, cartilage slices were aseptically dissect-
ed and then dissociated enzymatically for 6 hr in 0.2% colla-
genase type II (381 U/mg solid, Sigma Louis, MO, U.S.A.) in
phosphate-buffered saline, and then individual cells were
obtained by collecting the supernatant after brief centrifu-
gation. The cells were resuspended in Dulbecco’s modified
Eagle’s medium (DMEM, Gibco-BRL, Gaithersburg, MD,
U.S.A.) supplemented with 10% (v/v) fetal bovine-calf serum,
50  g/mL streptomycin, and 50 units/mL penicillin, after
which they were plated on culture dishes at a density of 5×
104 cells/cm2. The medium was changed every 2 days after
seeding, and cells reached confluence in approximately 5 days.
Differentiation status of articular chondrocytes was determined
by examining the accumulation of sulfated glycosaminogly-
can with Alcian blue staining or expression of type II collagen
(Chemicon, Temecula, CA, U.S.A.) by immunoblot analysis
as described previously (23).
Immunoblot analysis
Whole cell lysates were prepared by extracting proteins
using a buffer containing 50 mM Tris-HCl, pH 7.4, 150
mM NaCl, 1% Nonidet P-40, and 0.1% sodium dodecyl-
sulfate, supplemented with protease inhibitors (10  g/mL
leupeptin, 10  g/mL pepstatin A, 10  g/mL aprotinin and
1 mM of 4-[2-aminoethyl] benzenesulfonyl fluoride) and
phosphatase inhibitors (1 mM NaF and 1 mM Na3VO4). The
proteins were size-fractionated by SDS-polyacrylamide gel
electrophoresis and transferred to a nitrocellulose membrane.
The nitrocellulose sheet was then blocked with 3% non-fat
dry milk in Tris-buffered saline. COX-2 was detected using
antibody purchased from Cayman Chemical (Ann Arbor, MI,
U.S.A.). SOX-9, ERK-2, and PPAR- were detected using
antibodies purchased from Santa Cruz Biotech (Santa Cruz,
CA, U.S.A.). The bands were visualized using peroxidase-con-
jugated secondary antibodies and chemiluminescence.
Immunohistochemistry 
Rabbit joint cartilage explants or arthritic cartilage were
fixed in 4% paraformaldehyde in PBS for 24 hr at 4℃, wash-
ed with PBS, dehydrated with graded ethanol, embedded
in paraffin, and sectioned at 4- m thickness. The sections
were stained by standard procedures using Alcian blue or
antibody against type II collagen or COX-2 and visualized
by developing with a kit purchased from DAKO (Carpinte-
ria, CA, U.S.A.), following the procedure recommended by
the manufacturer. 
PGE2 assay
PGE2 production was determined by measuring the levels
of cellular and secreted PGE2 using an assay kit (Amersham
Pharmacia Biotech, NJ, U.K.). Briefly, chondrocytes were
seeded in standard 96-well microtiter plates at 2×104 cells/
well. Following addition of the indicated pharmacological
reagents, supernatant was used to quantify the amount of
PGE2, according to the manufacturer’s protocol. PGE2 levels
were calculated against a standard curve of PGE2 and norma-
lized against the amount of genomic DNA. 
Transfection and reporter assays
The reporter construct (3xPPRE-TK-luc/pGL3) used in the
transfections contained three copies of the peroxisome prolif-
erator response element (PPRE) site from the aP2 enhancer
(ARE7) inserted upstream of a minimal thymidine kinase
(TK) promoter in the pGL3 basic luciferase vector and RXR
cDNA (a gift from Dr. JB, Kim at Seoul National University).
Transfection of the reporter vector was performed as described
previously (23). Chondrocytes cells were grown in 10% fetal
calf serum/DMEM and co-transfected with various reporter
plasmids (1  g) and pCMV  -galactosidase plasmid (0.5  g)
(Clontech, Palo Alto, CA, U.S.A.) using Lipofectamine (Life
Technologies, Inc., Grand island, NY, U.S.A.), following the
procedure recommended by the manufacturer. The transfect-
ed cells were cultured in complete medium for 24 hr and used
for further assay. Cells were treated with increasing concentra-
tions (0-20  M) or times (0-24 hr) of 15d-PGJ2. Luciferase
and  -galactosidase activities were determined in all extracts
using a Luciferase assay (Promega, Madison, WI, U.S.A.) and
Galacto-light system (Tropix, Inc., Bedford, MA, U.S.A.). The
activities were corrected for transfection efficiency with  -gal
activity and expressed as fold-induction relative to the levelin untreated cells. Each assay was performed in triplicate. Data
are the mean +/- SD of three separate experiments performed
with cells from different animals (**pd 0.01 versus non treat-
ed cells).
Reverse transcriptase polymerase chain reaction
(RT-PCR)
Primary culture chondrocytes were treated with 15d-PGJ2.
Total RNA was isolated using RNA STAT-60 (Tel-Test B,
Inc., Friendswood, TX, U.S.A.) and reverse-transcribed with
MoMLV-RT (Invitrogen, California, U.S.A.) as previously
described (26). The following primers and conditions were
used for PCR in rabbit articular chondrocytes: for type II
collagen (370-bp product), 5′ -GAC CCC ATG CAG TAC
ATG CG-3′(sense) and 5′ -AGC CGC CAT TGA TGG
TCT CC-3′(antisense) with an annealing temperature of 55
℃; for SOX-9 (386-bp product), 5′ -GCG CGT GCA GCA
CAA GAA GGA CCA CCC GGA TTA CAA GTA C-3′
(sense) and 5′ -CGA AGG TCT CGA TGT TGG AGA TGA
CGT CGC TGC TCA GCT C-3′ (antisense) with an anneal-
ing temperature of 62℃; for COX-2 (298 bp product), 5′ -
TCA GCC ACG CAG CAA ATC CT-3′ (sense) and 5′ -GTG
ATC TGG ATG TCA GCA CG-3′ (antisense) with an anneal-
ing temperature of 52℃ for glyceraldehydes 3-phosphate
dehydrogenase (GAPDH; 299-bp products), 5′ -TCA CCA
TCT TCC AGG AGC GA-3′ (sense) and 5′ -CAC AAT GCC
GAA GTG GTC GT-3′(antisense) with an annealing tem-
perature of 50℃ The primers for rabbit type II collagen and
rabbit SOX-9 were de- signed based on the sequence of human
homologs, and sequencing of PCR product showed 89% and
93% homology with corresponding human genes.
Data analyses and statistics
The results are expressed as the means±S.E. values calcu-
lated from the specified number of determinations. Analysis
of variance (ANOVA) was performed to compare individual
treatments with their respective control values. The Turkey’s
honestly significant difference method was employed when
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Fig. 1. 15d-PGJ2 causes dedifferentiation of articular chondrocytes. (A) Primary culture chondrocytes were treated with the PPAR- acti-
vator 15d-PGJ2 (10  M) for various time periods (upper panel, A) or with the indicated concentrations of 15d-PGJ2 for 24 hr (lower panel,
A). Expression of type II collagen and SOX-9 was detected using immunoblot analysis. (B) Articular chondrocytes were left untreated (con)
or were treated with 10  M 15d-PGJ2 for 24 hr, and expression of type II collagen, SOX-9, and GAPDH was determined by RT-PCR. GA-
PDH was used as loading controls. (C) and (D) Accumulation of sulfated glycosaminoglycan was quantified by Alcian blue staining. The
data represent results of a typical experiment (A and B) or mean values±S.D. (C and D) from at least four independent experiments. The
letters on the bar indicate significant differences among means (n=5) at p=0.05 using the Turkey’s honestly significant difference method.
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making multiple comparisons among means (24).
RESULTS
15d-PGJ2 induces dedifferentiation in articular chondro-
cytes
To examine the effects of 15d-PGJ2 on articular cartilage
chondrocyte differentiation, rabbit articular chondrocytes in
primary culture were treated with 10  M 15d-PGJ2 for 48
hr. Under these experimental conditions 15d-PGJ2 displayed
no cytotoxicity, as assessed by the conversion of a tetrazolium
compound to its formazan product, as well as trypan blue
exclusion (data not shown). 15d-PGJ2 inhibited type II col-
lagen, a marker for differentiation of chondrocytes, and SOX-
9 expression, a major transcription factor that regulates type
II collagen expression, in a dose- and time-dependent man-
ner as determined by immunoblot analysis (Fig. 1A). RT-
PCR also showed that expression of type II collagen and SOX-
9 was reduced (Fig. 1B). Similarly, 15d-PGJ2 treatment of
primary culture cells blocked the accumulation of sulfated
proteoglycan in a dose- and time-dependent manner (Fig.
1C, D). The effects of rosiglitazone, a PPAR- natural lig-
and, on dedifferentiation and COX-2 expression in articular
chondrocytes showed the same results (data not shown). These
results indicate that 15d-PGJ2 induces dedifferentiation of
articular chondrocytes in primary culture cells.
15d-PGJ2 increases COX-2 expression and PGE2
production in articular chondrocytes
The effect of 15d-PGJ2 on COX-2 expression and PGE2
production was investigated using primary culture chondro-
cytes. In chondrocytes, 15d-PGJ2 increased protein levels of
COX-2 in a time- and dose-dependent manner as determin-
ed by immunoblot analysis (Fig. 2A). COX-2 expression was
increased 1 hr after 15d-PGJ2 treatment, and the levels peak-
ed at 6 hr. 15d-PGJ2 treatment, however, did not affect PPAR-
expression levels. 15d-PGJ2 also enhanced COX-2 expres-
Fig. 2. 15d-PGJ2 induces COX-2 expression and PGE2 production in articular chondrocytes. (A) Primary culture chondrocytes were treated
with 15d-PGJ2 (10  M) for various time periods (upper panel, A) or with the indicated concentrations of 15d-PGJ2 for 24 hr (lower panel,
A). Expression of COX-2 and PPAR- was detected using immunoblot analysis. (B) Articular chondrocytes were left untreated (con) or
were treated with 10  M 15d-PGJ2 for 24 hr, and expression of COX-2 and GAPDH was determined by RT-PCR. GAPDH was used as
loading controls. (C) and (D) PGE2 production was measured using an PGE2 assay kit and normalized by determining the amount of total
genomic DNA. The data represent results of a typical experiment or mean values±S.D. from at least four independent experiments. The
letters on the bar indicate significant differences among means (n=5) at p=0.05 using the Turkey’s honestly significant difference method.
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sion as determined by RT-PCR (Fig. 2B). Consistent with
the induction of COX-2 expression, 15d-PGJ2 stimulated
PGE2 production in a time- and dose-dependent manner
(Fig. 2C, D). The production of PGE2 was determined by
using a PGE2 assay kit. PGE2 levels were calculated against
a standard curve of PGE2. These data indicate that 15d-PGJ2
not only causes dedifferentiation of articular chondrocytes but
also stimulates COX-2 expression and PGE2 production.
15d-PGJ2 causes dedifferentiation and induction of 
COX-2 expression in cartilage explants
To examine the effects of 15d-PGJ2 on articular cartilage
chondrocyte dedifferentiation and COX-2 expression, carti-
lage explant cultures were treated with 10  M 15d-PGJ2
for 24 hr, and cartilage-specific matrix molecules were deter-
mined. 15d-PGJ2 caused a dramatic loss of type II collagen
(Fig. 3, middle panel) and sulfated proteoglycans (Fig. 3, left
panel) as determined by immunohistochemical staining and
Alcian blue staining, respectively. However, 15d-PGJ2 stim-
ulated COX-2 expression (Fig. 3, right panel) as determined
by immunohistochemical staining. These data indicate 15d-
PGJ2 also induces dedifferentiation and COX-2 expression
in cartilage explants. 
15d-PGJ2 stimulates PPAR- -activation in articular
chondrocytes
To determine whether the PPAR- expressed in the rabbit
articular chondrocytes were transcriptionally active, a PPRE
cloned upstream of luciferase (3xPPRE-TK-Luc/pGL3) was
transiently transfected into articular chondrocyte cells, and
the cells were then treated with 15d-PGJ2. As expected, ex-
pression of luciferase activity was significantly induced after
15d-PGJ2 treatment in a time- and dose-dependent manner
(Fig. 4). The transfection efficiency was above 40% efficien-
cy. These results indicate that 15d-PGJ2 increased PPAR-
transcription activity in articular chondrocytes.
15d-PGJ2 regulates on dedifferentiation via PPAR- -
dependent pathway but not COX-2 expression 
Because 15d-PGJ2 in articular chondrocytes causes both
dedifferentiation and COX-2 expression/PGE2 production,
we next examined whether PPAR- activation is associated
with dedifferentiation and/or COX-2 expression and PGE2
production. 15d-PGJ2-induced inhibition of type II colla-
gen and SOX-9 expression was prevented by the addition of
10  M BADGE (bisphenol A diglycidyl ether, PPAR- an-
tagonist) (Fig. 5A). The 15d-PGJ2-induced inhibition of
sulfated proteoglycan on primary culture chondrocytes was
Fig. 3. 15d-PGJ2 causes dedifferentiation and COX-2 expression
in articular chondrocytes. Cartilage explants were untreated or
treated with 10  M 15d-PGJ2 for 24 hr. Type II collagen, COX-2,
and proteoglycan were detected by immunohistochemical stain-
ing and Alcian blue staining, respectively. The data represent
results of a typical experiment conducted at least four times. 
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Fig. 4. 15d-PGJ2 stimulates PPAR- transcriptional activity. Primary culture chondrocytes cells were co-transfected with reporter plasmids
(3xPPRE-TK-Luc/pGL3) and RXR expression plasmids (RXR /pSG5). pCMV  -galactosidase plasmid was used as an internal control
for the transfection efficiency. Transfected cells were treated with 15d-PGJ2 (10  M) for various time periods (A) or with the indicated con-
centrations of 15d-PGJ2 for 24 hr (B). The cell extracts was assayed for luciferase activity and  -galactosidase activity. The data represent
results of a typical experiment or mean values±S.D. from at least four independent experiments. The letters on the bar indicate significant
differences among means (n=5) at p=0.05 using the Turkey’s honestly significant difference method.
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DGE did not affect 15d-PGJ2-stimulated COX-2 expres-
sion (Fig. 5A) or PGE2 production (Fig. 5C). To elucidate
the dedifferentiation mechanism, we examined PPAR- -res-
ponse element (PPRE)-luciferase activity. As shown in Fig.
5D, 15d-PGJ2-enhanced PPAR- activity was blocked by
BADGE pretreatment. On the basis of these results, we sug-
gest that 15d-PGJ2 regulates dedifferentiation via a PPAR-
-dependent pathway and COX-2 expression/PGE2 produc-
tion via a PPAR- -independent pathway. 
DISCUSSION
Chondrocytes in normal articular cartilage are a unique
cell type in that their differentiated phenotype is reversible.
Chondrocyte phenotype is regulated by a balance of anabol-
ic and catabolic molecular reactions that are involved in main-
taining homeostasis of cartilage tissue (23). Differentiated
chondrocytes lose their phenotype and transform into fibrob-
last-like cells upon exposure to soluble factors IL-1 (25),
and nitric oxide (26) or during serial subculture in vitro (23).
Such a destruction of homeostasis is believed to be involved
in the pathophysiology of arthritis (27). 
It was shown previously that 15d-PGJ2 has anti-inflam-
matory effects on both human chondrocytes (10) and rheu-
matoid synovial fibroblasts (28). However, the present study
demonstrated the pro-inflammatory effect of 15d-PGJ2 in
rabbit articular chondrocytes, suggesting a catabolic role of
15d-PGJ2 in cartilage. Thus far, controversy still remains
regarding the role of 15d-PGJ2 in inflammatory responses
(29). Indeed, the 15d-PGJ2 pathway has been shown to have
anti- and pro-inflammatory effect (29), depending on exper-
imental conditions and/or cell types.
PPAR- is constitutively expressed in articular chondro-
cytes as shown by immunoblot in Fig. 2A. The presence of
the expression of the PPAR- in chondrocytes may provide
a new insight in the understanding of the mechanisms which
lead to the loss of cartilage homeostasis. Under inflammato-
ry and pathologic conditions, however, PPAR- plays an im-
portant role. Activation of this nuclear receptor by 15d-PGJ2
has been shown to be critical for the induction of rheumatoid
arthritis and osteoarthritis. PPAR- thus deserves consider-
ation for clinical testing in degenerative cartilage diseases (30). 
In this study, we demonstrated that an increase in PPAR-
activities is required for 15d-PGJ2-induced dedifferentiation
of rabbit knee joint articular chondrocytes. However, 15d-PGJ2
treatment PPAR- activity is not required for inflammatory
responses (i.e. COX-2 expression/PGE2 production). Thus,
15d-PGJ2-induced COX-2 expression/PGE2 production is
mediated by a PPAR- -independent pathway. In 1995, 15d-
PGJ2 was reported to be a high-affinity ligand for PPAR- ,
and diverse of its effects have been attributed to the activation
of this nuclear receptor (11). However, there is increasing evid-
ence that 15d-PGJ2 has diverse PPAR- -independent effects
(31). Therefore, further studies are necessary to elucidate infl-
ammatory responses-related different signaling mechanisms.
In summary, current knowledge indicates that PPAR-
plays a key role in the regulation of dedifferentiation in artic-
ular chondrocytes.
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